logo-loader
IXICO PLC

IXICO PLC secures significant new contracts with two new clients

IXICO PLC's (LON:IXI) John Hall came into Proactive London to discuss two significant new contracts they've agreed with new biopharmaceutical clients.

The first contract, to support an early phase study into Huntington’s Disease (HD), is worth around £2mln and will be delivered over seven years.

The other's for a Phase 3 study for another rare neurological disease.

Quick facts: IXICO PLC

Price: £0.54

Market: AIM
Market Cap: £25.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: IXICO CFO Grant Nash joins board and discusses 'strong' 2019...

IXICO PLC (LON:IXI) CFO Grant Nash says the firm's performance for the current year will be materially ahead of market expectations - benefitting from new and expanded contracts, the deployment of newly-developed algorithms and faster turnaround times in trial initiation. Nash, who was...

4 weeks ago

RNS

Director/PDMR Shareholding

1 week, 2 days ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 2 days ago

Issue of Equity

3 weeks, 2 days ago

Directorate Change

4 weeks, 1 day ago

2 min read